TNFSF11 and osteosarcoma: Another antibody-drug being studied for the treatment of osteosarcoma is Denosumab, a fully human monoclonal antibody that binds RANK-L with high specificity and affinity and induces a reduction of OCs maturation and, consequently, of bone erosion [98,172].